V
valinordiscovery.com
AI-driven clinical insight — predicting therapeutic success before trials begin
About valinordiscovery.com
Valinor Discovery is a biotechnology company at the forefront of applying machine learning and computational modeling to transform how new drugs are developed and evaluated. Drug discovery and clinical development are traditionally slow, costly, and high-risk processes, with most candidates failing late in development after years of investment. Valinor addresses this challenge by building advanced AI models that simulate how therapies perform in virtual patients before they ever reach clinical trials, enabling smarter, faster, and more cost-effective decision-making.
The company’s platform leverages large-scale, longitudinal biological and clinical datasets — including multi-omics, functional assays, and patient-level clinical data — to construct realistic, patient-centric simulations of disease progression and treatment response. By modeling entire biological systems rather than isolated mechanisms, Valinor provides insights into efficacy, safety signals, patient stratification, biomarker discovery, and trial design at an early stage of development. This holistic approach allows biopharmaceutical companies to prioritize the most promising candidates, refine therapeutic strategies, and reduce late-stage failure risk.
Valinor Discovery partners with pharmaceutical companies, biotech firms, and research institutions, offering its technology through secure, compliant platforms that integrate into existing R&D workflows. By shifting critical learning upstream and replacing parts of traditional trial-and-error experimentation with predictive simulation, Valinor aims to fundamentally improve the efficiency of drug development and accelerate the delivery of effective treatments to patients worldwide.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Boston, United States
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 76.3/100
- Industry
- Health, Enterprise Software
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, out of stealth, science-based
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Dec 2025 | $14M | $57M | CRV · Pelion Venture Partners · Harpoon · Amino Collective | ↗ |
Growth signals
Latest recorded traffic for valinordiscovery.com is 1.7K monthly website visits, up 41.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
CRV
Pelion Venture Partners
Harpoon
Amino Collective
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about valinordiscovery.com on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See valinordiscovery.com’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







